1REGN trade ideas
Regeneration Pharma Looking for reversal $regn
The stock has had a parabolic move in 2020, but for how long can that continue,
a healthy pullback will be needed entice new investors.
Levels are identified on chart for possible short and long entries
Regeneron Bullish Case $regn
Major recruitment drive underway in Ireland on National radio, positions need to be filled urgently.
Very bullish for the stock.
Top of channel target minimum
Regeneron Pharma Inc Fast-track Covid-19 drugRegeneron announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated hundreds of virus-neutralizing, fully human antibodies from the company's VelocImmune mice, which have been genetically-modified to have a human immune system. Regeneron has also isolated antibodies from humans who have recovered from COVID-19, in order to maximize the pool of potentially potent antibodies. From this large pool of candidates, Regeneron will select the top two antibodies for a 'cocktail' treatment based on potency and binding ability to the SARS-CoV-2 spike protein, as well as other desirable qualities. Using a multi-antibody approach allows for targeting of different parts of the virus and may help protect against multiple viral variants. Regeneron previously used these technologies to rapidly develop a successful treatment for Ebola virus infection, which is currently under review by the U.S. FDA. In order to meet the pressing public health need, Regeneron is applying its VelociMab technology to prepare manufacturing-ready cell lines as lead antibodies are selected, so that clinical-scale production can begin immediately. The company is working toward the goal of producing hundreds of thousands of prophylactic doses per month by the end of summer and hopes to have smaller quantities available for initial clinical testing at the beginning of the summer. The company is working with the U.S. Health & Human Services' Biomedical Advanced Research and Defense Authority to increase capacity even further. "Our three decades of investment in our VelociSuite antibody technologies, which accelerate and improve the traditional drug discovery process, have hopefully prepared us for this critical time and to meet this important challenge," said George D. Yancopoulos, M.D., Ph.D., Co-founder, President and Chief Scientific Officer of Regeneron. "Given the tremendous interest and concern around the COVID-19 pandemic, we will be providing regular and transparent updates on our discovery and development programs. I want to recognize our incredible team, which is working around the clock to develop needed solutions to this global health crisis." All coronaviruses have a single glycoprotein on the virus surface called the spike protein, which is the protein on the virus cell surface that binds to the host cell and is required for infectivity. Regeneron's SARS-CoV-2 antibodies will target the spike protein in order to block its interaction with the host cell, and thus neutralize the virus.
Source thefly.com
REGN - Bullish impulse on its way to set some new recordsOne of few stocks bullish and perhaps for good reasons given the coron virus. Someone has more time to do fundamental analysis to back up this technicals, feel free to drop me a line
Saham syarikat REGNREGN adalah kod bagi syarikat Regeneron Pharmaceuticals Inc yang diperbuat dari segi sektor penjagaan Kesihatan. Mengikut pemerhatian gelombang sahlun tentang saham ini adalah uptrend@bullish dengan kenaikkan sebanyak 24.87% dalam tempoh 3 bulan lepas. Dari segi Syariah, saham ini adalah Patuh Syariah
Spy weekend recap not much has changed on the daily on the $SPY but, the weekly. We are on the support so one or two ways traders should determine the outcome should we continue with the selling off or just accepted it and regain control of the situation? on the weekly what I would like to see in a flip and regain the sell off. If you saw my 3/5 (LINK) post then you get the idea. Let's go on the little adventure: $REGN (WKLY) up into retake the $522.96 territory? same with $GILD (Daily) $INO can this continue or reverse and puke ?
Regeneron Pharma breakout watch $regn
Alert set for break above $465 for possible long.
Caution as RSI is at historical resistance.
Expect back-test of downtrend is broken through
Regeneron rejecting new highs? Nice bearish engulfing pattern formed on REGN today, confirming the resistance level above the last bearish engulfing pattern in January 2020.
Bot near Friday Close A bit risky. Seems to have supported by 50% Fib and the gap. Potential catalyst of corona.
$REGN 12-1 AnalysisHard move up after reclaiming 200DMA(red). Being held up steadily by the 9DMA(green). Very overbought and gap has been filled from most recent dramatic drop in April. Look for consolidation around 9/13 soon before moves further up. No confirmation yet of slowdown though. On watch.
$REGN Buy signal in Regeneron PharmaEntry level $345 = Target price $375 = Stop loss $336
Bullish reversal occurring in regenerson after quite a sustained correction.
Historical buy signal is complete on the weekly chart, the daily chart is a little overbought so we await a break in the weekly RSI for a safer entry.
Average analysts price target $383 | Overweight.
P/E ratio 18.78.
Company profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
